Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Somayeh Vafaei
 -- 1541 2023-12-13 17:38:39 |
2 Reference format revised.
Lindsay Dong
+ 5 word(s) 1546 2023-12-19 03:42:32 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Vafaei, S.; Ciebiera, M.; Omran, M.M.; Ghasroldasht, M.M.; Yang, Q.; Leake, T.; Wolfe, R.; Ali, M.; Al-Hendy, A. Anti-Uterine Fibroids Diet. Encyclopedia. Available online: https://encyclopedia.pub/entry/52704 (accessed on 19 July 2024).
Vafaei S, Ciebiera M, Omran MM, Ghasroldasht MM, Yang Q, Leake T, et al. Anti-Uterine Fibroids Diet. Encyclopedia. Available at: https://encyclopedia.pub/entry/52704. Accessed July 19, 2024.
Vafaei, Somayeh, Michał Ciebiera, Mervat M. Omran, Mohammad Mousaei Ghasroldasht, Qiwei Yang, Tanya Leake, Rochelle Wolfe, Mohamed Ali, Ayman Al-Hendy. "Anti-Uterine Fibroids Diet" Encyclopedia, https://encyclopedia.pub/entry/52704 (accessed July 19, 2024).
Vafaei, S., Ciebiera, M., Omran, M.M., Ghasroldasht, M.M., Yang, Q., Leake, T., Wolfe, R., Ali, M., & Al-Hendy, A. (2023, December 13). Anti-Uterine Fibroids Diet. In Encyclopedia. https://encyclopedia.pub/entry/52704
Vafaei, Somayeh, et al. "Anti-Uterine Fibroids Diet." Encyclopedia. Web. 13 December, 2023.
Anti-Uterine Fibroids Diet
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms242115972

Uterine fibroids (UFs) are common tumors in women of reproductive age. It is imperative to comprehend UFs’ associated risk factors to facilitate early detection and prevention. Simple relying on surgical/pharmacological treatment of advanced disease is not only highly expensive, but it also deprives patients of good quality of life (QOL). Nutrition plays a crucial role in the management of UFs, adopting a personalized dietary regimen that includes specific foods, supplements, and vitamins can help reduce the risk of UFs, prevent their further growth, and alleviate symptoms. In accordance with the ESCAPE protocol, the incorporation of vitamin D (4000 IU/day), Epigallocatechin Gallate (EGCG) (800 mg/day), and the use of endocrine-disrupting chemical (EDC)-free products can be regarded as both safe and effective. These options also present an economically viable approach, particularly for women who have undergone myomectomy to deter fibroid recurrence, as well as for those exhibiting early symptoms and evident findings on imaging.

uterine fibroid leiomyoma Diet

1. Introduction

Uterine fibroids (UFs), also known as leiomyomas or myomas, represent a significant global health issue, impacting a substantial portion of reproductive age women, with estimates suggesting that they affect even up to 80% of women worldwide [1][2]. The burden of UFs on a global scale has markedly increased, with a rise in both incidences and disability-adjusted life years [3][4]. This increase is particularly prominent in regions with a lower sociodemographic index, indicating a pressing need for immediate attention to be given to health protection of underprivileged communities [5]. Unfortunately, UFs are often accompanied by distressing symptoms, which can significantly impact the well-being of those affected. These symptoms include heavy menstrual bleeding (HMB) leading to anemia [6], painful periods, pelvic pain or pressure, abdominal swelling or bloating, and discomfort during sexual intercourse, frequent urination, constipation, back or leg pain, infertility, or miscarriage [7]. The presence of these symptoms underscores the importance of addressing UFs and finding effective management strategies to improve the quality of life (QOL) for individuals experiencing them [8][9].
Although the etiology of UFs is not fully understood, several risk factors, including age, race, obesity, parity, hypertension, vitamin D deficiency, hormonal imbalances, exposure to endocrine-disrupting chemicals (EDCs) (organophosphate esters and plasticizers) [10][11], genetic polymorphism, and lifestyles involving a worse diet, lack of physical activity, and high stress have been identified [12][13]. Furthermore, some of the variations in UFs’ risk and the racial disparities associated with UF traits can be attributed to genetic differences among various geographic populations. UFs disproportionately affect black women, who not only experience UFs at an earlier age but also face a higher overall risk [14][15]. Given these factors, even seemingly healthy individuals should be mindful of preventive measures.
Primary prevention involves measures to prevent disease in healthy individuals by either reducing risk exposure or enhancing immunity. It aims to halt the disease’s development in high risk before it even starts [16]. Currently, there is no well-established screening test for UFs and, as such, no viable approach for primary prevention, However, scholars are pursuing this important goal [17]. UFs are diagnosed mostly by bimanual pelvic test, especially in advanced disease in thin patients. Imaging usually using ultrasonography and occasionally using magnetic resonance imaging (MRI), or computed tomography (CT) is the most common method to diagnose UF [2][18][19]. Imaging allows proper evaluation of the disease such as the size, location, and multiplicity of UFs. Two crucial aspects in contemporary approaches to optimal treatment include the concepts of shared decision making and the availability of personalized therapy options, which may include a “watchful waiting” approach determined by the patient’s symptoms, their individual treatment objectives, and the physician’s assessment. Medical treatment included non-hormonal and hormonal approaches. Non-hormonal like catechol-O-methyl transferase. (COMT) inhibitors, vitamin D [20][21], vitamin D receptors (VDR) agonists, epigallocatechin gallate (EGCG), localized gene therapy, nanoparticles, and localized bacterial collagenase [22][23][24][25][26]. Hormone therapy such as gonadotropin-releasing hormone (GnRH) agonists and antagonist, selective progesterone receptor modulators (SPRMs), aromatase inhibitors or progestin-releasing intrauterine devices (IUDs) [27][28]. Surgery consists of traditional (abdominal myomectomy and hysterectomy) or minimally invasive or noninvasive procedures (laparoscopic or robotic myomectomy and hysterectomy, uterine artery embolization, radiofrequency ablation or endometrial ablation, MRI or ultrasound guided focused ultrasound surgery (FUS), may sometimes be necessary to remove or shrink large or symptomatic UFs [29][30][31][32][33]. Annual direct and indirect UFs costs range from $5.9 to $34.4 billion for United States of America women seeking treatment. UFs complicated by HMB were associated with significantly higher direct health care costs compared with UFs or HMB alone [34][35].
Secondary prevention involves detecting early-stage diseases in individuals with subtle signs of illness. This phase is especially relevant for women concerned about UF recurrence post-surgery. Strategies are pursued to prevent disease advancement or recurrence [36]. In the context of secondary prevention, screenings are frequently employed as a mean to achieve early disease detection and intervention. Currently, there is no validated method for screening pre-symptomatic health women for risk of future UFs development [37][38].

2. Anti-UF Diet

Following long-lasting RCT or a long cohort showing that nutrition plays a crucial role in the management of UFs, adopting a personalized dietary regimen that includes specific foods, supplements, and vitamins can help reduce the risk of UFs, prevent their further growth, and alleviate symptoms [39]. A low intake of fruit and green vegetables and pollutants ingested with food is linked to a higher risk of myoma formation [40][41]. This includes incorporating vegetables rich in fiber, such as leafy greens, cruciferous vegetables, carrots, sweet potatoes, and bell peppers, which provide essential nutrients and antioxidants that combat inflammation and support hormonal balance [42]. Based upon observational and epidemiological investigations [43], adding fruits like berries, citrus fruits, apples, pineapple, and kiwi to the diet contributes antioxidants, anti-inflammatory compounds, and enzymes that may reduce the risk of UF growth [44]. Omega-3 fatty acids found in fatty fish, flaxseed, chia seeds, walnuts, nuts, and seeds have anti-inflammatory properties that can modulate inflammation associated with UF development [45]. Incorporating fish and lean meats like skinless chicken and egg whites provides high-quality protein and essential nutrients [46]. By following a comprehensive approach that includes a UF-preventive diet along with exercise, stress management, and medical guidance, individuals can promote gynecological health and potentially reduce the risk of UFs.
In contrast, there are certain food items that women are advised to decrease or eliminate intake as they may potentially worsen the condition. Red meat, particularly processed and unprocessed beef and pork, contains high levels of saturated fats and potentially harmful compounds that can promote inflammation and hormonal imbalances in the body [47]. While more research is needed to establish a definitive link between red meat and UFs, it is generally recommended to maintain a balanced and varied diet with moderate red meat intake [48]. High-fat dairy products, which can contain high levels of estrogen and contribute to inflammation, are also believed to have a negative influence on fibroids. Choosing low-fat or skim dairy products as part of a balanced diet may be beneficial for individuals with UFs [15]. Caffeine, found in coffee, tea, energy drinks, and some sodas, has conflicting evidence regarding its impact on UFs [49]. Some studies suggest an increased risk with high caffeine intake, as caffeine can affect estrogen levels [48]. However, individual responses to caffeine can vary, and reducing caffeine intake may help alleviate symptoms for some women. The relationship between alcohol consumption and UFs is not fully understood, but excessive alcohol intake can lead to hormonal imbalances and impair liver function, potentially impacting hormone levels and UF development or progression. Moderate alcohol consumption may not have significant adverse effects, but excessive or chronic intake can be detrimental to overall health. It is important for women with UFs to discuss alcohol consumption with their healthcare provider to make informed decisions [50][51][52].
The utilization of natural compounds in the prevention and management of UFs holds promise for improved gynecological health. Curcumin, a natural phenol found in turmeric, exhibits anti-inflammatory and antioxidant properties that may have therapeutic potential in managing UFs [53][54][55]. Flaxseed, rich in lignans, is believed to have anti-inflammatory and antioxidant effects that could benefit individuals with UFs [56]. Resveratrol, present in mulberries, peanuts, and grapes [57], shows promise as an anti-fibrotic therapy by reducing ECM-related proteins and inhibiting UF cell proliferation [58][59]. Berberine, derived from plants like Scutellaria barbata, selectively inhibits UF cell proliferation induced by estrogen and progesterone, making it a potential targeted therapeutic option [60][61]. Methyl jasmonate obtained from jasmine plants demonstrates anti-EZH2 activity, suggesting its potential as a UF treatment [62]. Quercetin, found in various fruits and vegetables, modulates UF cell migration and gene expression [63], while sulforaphane, abundant in cruciferous vegetables, inhibits fibrotic processes associated with UFs [64]. Fucoidans, derived from brown seaweeds, exhibit antioxidant and anti-inflammatory properties and may attenuate UF progression [65]. Indole-3-carbinol, commonly found in cruciferous vegetables, regulates ECM components and cellular proliferation in UFs [66]. Isoliquiritigenin, present in licorice family plants, inhibits UF cell proliferation and activates apoptotic pathways [67][68]. Anthocyanins, lycopene, and vitamin A found in fruits and vegetables may contribute to UF prevention, but further research is required [69]. Chinese herbal preparations like Gui Zhi Fu Ling and Nona Roguy show potential in UF management [70][71]. Genistein, derived from soybeans, induces novel cell death pathways in UF cells [72]. Minerals like selenium and magnesium may have therapeutic effects on UFs, while probiotics promote a healthy gut microbiome, potentially reducing UF risk [73]. Incorporating whole grains into the diet may help maintain hormonal balance and reduce UF risk. It is important to consult healthcare professionals for personalized guidance on the usage of these natural compounds for UFs.

References

  1. Borah, B.J.; Nicholson, W.K.; Bradley, L.; Stewart, E.A. The impact of uterine leiomyomas: A national survey of affected women. Am. J. Obstet. Gynecol. 2013, 209, 319.e1–319.e20.
  2. Sefah, N.; Ndebele, S.; Prince, L.; Korasare, E.; Agbleke, M.; Nkansah, A.; Thompson, H.; Al-Hendy, A.; Agbleke, A.A. Uterine fibroids—Causes, impact, treatment, and lens to the African perspective. Front. Pharmacol. 2022, 13, 1045783.
  3. Anneveldt, K.J.; Nijholt, I.M.; Schutte, J.M.; Dijkstra, J.R.; Frederix, G.W.J.; Ista, E.; Verpalen, I.M.; Veersema, S.; Huirne, J.A.F.; Hehenkamp, W.J.K.; et al. Comparison of (Cost-)Effectiveness of Magnetic Resonance Image-Guided High-Intensity-Focused Ultrasound with Standard (Minimally) Invasive Fibroid Treatments: Protocol for a Multicenter Randomized Controlled Trial (MYCHOICE). JMIR Res. Protoc. 2021, 10, e29467.
  4. Giuliani, E.; As-Sanie, S.; Marsh, E.E. Epidemiology and management of uterine fibroids. Int. J. Gynaecol. Obstet. 2020, 149, 3–9.
  5. Cheng, L.-C.; Li, H.-Y.; Gong, Q.-Q.; Huang, C.-Y.; Zhang, C.; Yan, J.-Z. Global, regional, and national burden of uterine fibroids in the last 30 years: Estimates from the 1990 to 2019 Global Burden of Disease Study. Front. Med. 2022, 9, 1003605.
  6. Kumari, S.; Swetha, P.; Nayak, S.; Singh, S. The Association Between Ferritin and Vitamin D Levels in Premenopausal Fibroid Uterus Cases with Anemia. Cureus 2021, 13, e13392.
  7. Anonymous. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet. Gynecol. 2021, 137, e100–e115.
  8. Soliman, A.M.; Margolis, M.K.; Castelli-Haley, J.; Fuldeore, M.J.; Owens, C.D.; Coyne, K.S. Impact of uterine fibroid symptoms on health-related quality of life of US women: Evidence from a cross-sectional survey. Curr. Med. Res. Opin. 2017, 33, 1971–1978.
  9. Al-Hendy, A.; Myers, E.R.; Stewart, E. Uterine Fibroids: Burden and Unmet Medical Need. Semin. Reprod. Med. 2017, 35, 473–480.
  10. Elkafas, H.; Badary, O.A.; Elmorsy, E.; Kamel, R.; Yang, Q.; Al-Hendy, A. Endocrine-Disrupting Chemicals and Vitamin D Deficiency in the Pathogenesis of Uterine Fibroids. J. Adv. Pharm. Res. 2021, 5, 260–275.
  11. Salehi, A.M.; Jenabi, E.; Farashi, S.; Aghababaei, S.; Salimi, Z. The environmental risk factors related to uterine leiomyoma: An umbrella review. J. Gynecol. Obstet. Hum. Reprod. 2023, 52, 102517.
  12. Yang, Q.; Ciebiera, M.; Bariani, M.V.; Ali, M.; Elkafas, H.; Boyer, T.G.; Al-Hendy, A. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr. Rev. 2021, 43, 678–719.
  13. He, Y.; Zeng, Q.; Dong, S.; Qin, L.; Li, G.; Wang, P. Associations between uterine fibroids and lifestyles including diet, physical activity and stress: A case-control study in China. Asia Pac. J. Clin. Nutr. 2013, 22, 109–117.
  14. Keaton, J.M.; Jasper, E.A.; Hellwege, J.N.; Jones, S.H.; Torstenson, E.S.; Edwards, T.L.; Edwards, D.R.V. Evidence that geographic variation in genetic ancestry associates with uterine fibroids. Hum. Genet. 2021, 140, 1433–1440.
  15. Stewart, E.; Cookson, C.; Gandolfo, R.; Schulze-Rath, R. Epidemiology of uterine fibroids: A systematic review. BJOG 2017, 124, 1501–1512.
  16. Kisling, L.A.; Das, M.J. Prevention Strategies. 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK537222/ (accessed on 22 September 2023).
  17. Ali, M.; Bariani, M.V.; Vafaei, S.; Omran, M.M.; Yang, Q.; Madueke-Laveaux, O.S.; Al-Hendy, A. Prevention of uterine fibroids: Molecular mechanisms and potential clinical application. J. Endometr. Uterine Disord. 2023, 1, 100018.
  18. De La Cruz, M.S.D.; Buchanan, E.M. Uterine Fibroids: Diagnosis and Treatment. Am. Fam. Physician 2017, 95, 100–107.
  19. Baird, D.D.; Harmon, Q.E.; Upson, K.; Moore, K.R.; Barker-Cummings, C.; Baker, S.; Cooper, T.; Wegienka, G. A Prospective, Ultrasound-Based Study to Evaluate Risk Factors for Uterine Fibroid Incidence and Growth: Methods and Results of Recruitment. J. Womens Health 2015, 24, 907–915.
  20. Markowska, A.; Kurzawa, P.; Bednarek, W.; Gryboś, A.; Mardas, M.; Krzyżaniak, M.; Majewski, J.; Markowska, J.; Gryboś, M.; Żurawski, J. Immunohistochemical Expression of Vitamin D Receptor in Uterine Fibroids. Nutrients 2022, 14, 3371.
  21. Catherino, W.H.; Eltoukhi, H.M.; Al-Hendy, A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin. Reprod. Med. 2013, 31, 370–379.
  22. Sharan, C.; Halder, S.K.; Thota, C.; Jaleel, T.; Nair, S.; Al-Hendy, A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil. Steril. 2011, 95, 247–253.
  23. Jayes, F.L.; Liu, B.; Moutos, F.T.; Kuchibhatla, M.; Guilak, F.; Leppert, P.C. Loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase Clostridium histolyticum. Am. J. Obstet. Gynecol. 2016, 215, 596.e1–596.e8.
  24. Roshdy, E.; Rajaratnam, V.; Maitra, S.; Sabry, M.; Allah, A.S.; Al-Hendy, A. Treatment of symptomatic uterine fibroids with green tea extract: A pilot randomized controlled clinical study. Int. J. Womens Health 2013, 5, 477–486.
  25. Brunengraber, L.N.; Jayes, F.L.; Leppert, P.C. Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids. Reprod. Sci. 2014, 21, 1452–1459.
  26. Kashani, B.N.; Centini, G.; Morelli, S.S.; Weiss, G.; Petraglia, F. Role of Medical Management for Uterine Leiomyomas. Best Pract. Res. Clin. Obstet. Gynaecol. 2016, 34, 85–103.
  27. Madueke-Laveaux, O.S.; Ciebiera, M.; Al-Hendy, A. GnRH analogs for the treatment of heavy menstrual bleeding associated with uterine fibroids. F&S Rep. 2023, 4 (Suppl. S2), 46–50.
  28. Ciebiera, M.; Madueke-Laveaux, O.S.; Feduniw, S.; Ulin, M.; Spaczynski, R.; Zgliczyńska, M.; Bączkowska, M.; Zarychta, E.; Łoziński, T.; Ali, M.; et al. GnRH agonists and antagonists in therapy of symptomatic uterine fibroids—Current roles and future perspectives. Expert. Opin. Pharmacother 2023, 24, 1799–1809.
  29. Sohn, G.S.; Cho, S.; Kim, Y.M.; Cho, C.-H.; Kim, M.-R.; Lee, S.R. Current medical treatment of uterine fibroids. Obstet. Gynecol. Sci. 2018, 61, 192–201.
  30. Ali, M.; Raslan, M.; Ciebiera, M.; Zaręba, K.; Al-Hendy, A. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert. Opin. Drug Saf. 2022, 21, 477–486.
  31. Ali, M.; Chaudhry, Z.T.; Al-Hendy, A. Successes and failures of uterine leiomyoma drug discovery. Expert. Opin. Drug Discov. 2018, 13, 169–177.
  32. McLaren, J.S.; Morris, E.; Rymer, J. Gonadotrophin receptor hormone analogues in combination with add-back therapy: An update. Menopause Int. 2012, 18, 68–72.
  33. Waibel-Treber, S.; Minne, H.W.; Scharla, S.H.; Bremen, T.H.; Ziegler, R.; Leyendecker, G. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Hum. Reprod. 1989, 4, 384–388.
  34. Wang, A.; Wang, S.; Owens, C.D.; Vora, J.B.; Diamond, M.P. Health Care Costs and Treatment Patterns Associated with Uterine Fibroids and Heavy Menstrual Bleeding: A Claims Analysis. J. Womens Health 2022, 31, 856–863.
  35. Pynnä, K.; Räsänen, P.; Roine, R.P.; Vuorela, P.; Sintonen, H. Where does the money go to? Cost analysis of gynecological patients with a benign condition. PLoS ONE 2021, 16, e0254124.
  36. Guo, X.C.; Segars, J.H. The impact and management of fibroids for fertility: An evidence-based approach. Obstet. Gynecol. Clin. N. Am. 2012, 39, 521–533.
  37. Pongpunprut, S.; Panburana, P.; Wibulpolprasert, P.; Waiyaput, W.; Sroyraya, M.; Chansoon, T.; Sophonsritsuk, A. A Comparison of Shear Wave Elastography between Normal Myometrium, Uterine Fibroids, and Adenomyosis: A Cross-Sectional Study. Int. J. Fertil. Steril. 2022, 16, 49–54.
  38. Bartels, C.B.; Cayton, K.C.; Chuong, F.S.; Holthouser, K.; Mehr, S.A.; Abraham, T.; Segars, J.H. An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review. Clin. Obstet. Gynecol. 2016, 59, 30–52.
  39. Fibroid, H. Here Are the Best and Worst Foods for Fibroids. 2022. Available online: https://houstonfibroids.com/posts/diet-and-exercise/food-and-drinks-to-avoid-if-you-have-uterine-fibroids/ (accessed on 22 September 2023).
  40. Tinelli, A.; Vinciguerra, M.; Malvasi, A.; Andjić, M.; Babović, I.; Sparić, R. Uterine Fibroids and Diet. Int. J. Environ. Res. Public Health 2021, 18, 1066.
  41. Parazzini, F.; Di Martino, M.; Candiani, M.; Viganò, P. Dietary components and uterine leiomyomas: A review of published data. Nutr. Cancer 2015, 67, 569–579.
  42. Shen, Y.; Wu, Y.; Lu, Q.; Ren, M. Vegetarian diet and reduced uterine fibroids risk: A case-control study in Nanjing, China. J. Obstet. Gynaecol. Res. 2016, 42, 87–94.
  43. Afrin, S.; AlAshqar, A.; El Sabeh, M.; Miyashita-Ishiwata, M.; Reschke, L.; Brennan, J.T.; Fader, A.; Borahay, M.A. Diet and Nutrition in Gynecological Disorders: A Focus on Clinical Studies. Nutrients 2021, 13, 1747.
  44. Davis, C.P.; Garzia, N.A.; Cushing-Haugen, K.; Terry, K.L.; Chiu, Y.-H.; Sandoval-Insausti, H.; Chavarro, J.E.; Missmer, S.A.; Harris, H.R. Fruit and vegetable consumption, pesticide residue intake from consumption of fruits and vegetables, and risk of uterine fibroids. F&S Sci. 2023, 4, 90–99.
  45. Islam, M.S.; Castellucci, C.; Fiorini, R.; Greco, S.; Gagliardi, R.; Zannotti, A.; Giannubilo, S.R.; Ciavattini, A.; Frega, N.G.; Pacetti, D.; et al. Omega-3 fatty acids modulate the lipid profile, membrane architecture, and gene expression of leiomyoma cells. J. Cell Physiol. 2018, 233, 7143–7156.
  46. Lambertino, A.; Turyk, M.; Anderson, H.; Freels, S.; Persky, V. Uterine leiomyomata in a cohort of Great Lakes sport fish consumers. Environ. Res. 2011, 111, 565–572.
  47. Chiaffarino, F.; Parazzini, F.; La Vecchia, C.; Chatenoud, L.; Di Cintio, E.; Marsico, S. Diet and uterine myomas. Obstet. Gynecol. 1999, 94, 395–398.
  48. Lucero, J.; Harlow, B.L.; Barbieri, R.L.; Sluss, P.; Cramer, D.W. Early follicular phase hormone levels in relation to patterns of alcohol, tobacco, and coffee use. Fertil. Steril. 2001, 76, 723–729.
  49. Leonard, T.K.; Watson, R.R.; Mohs, M.E. The effects of caffeine on various body systems: A review. J. Am. Diet Assoc. 1987, 87, 1048–1053.
  50. Nagata, C.; Nakamura, K.; Oba, S.; Hayashi, M.; Takeda, N.; Yasuda, K. Association of intakes of fat, dietary fibre, soya isoflavones and alcohol with uterine fibroids in Japanese women. Br. J. Nutr. 2009, 101, 1427–1431.
  51. Takala, H.; Yang, Q.; El Razek, A.M.A.; Ali, M.; Al-Hendy, A. Alcohol Consumption and Risk of Uterine Fibroids. Curr. Mol. Med. 2020, 20, 247–258.
  52. Kim, S.; Han, K.; Choi, S.-Y.; Yang, S.Y.; Choi, S.H.; Yim, J.Y.; Kim, J.J.; Kim, M.-J. Alcohol consumption and the risk of new-onset uterine leiomyomas: A nationwide population-based study in 2.5 million Korean women aged 20 to 39 years. Am. J. Obstet. Gynecol. 2023, 229, e1–e45.
  53. Ejaz, A.; Wu, D.; Kwan, P.; Meydani, M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J. Nutr. 2009, 139, 919–925.
  54. Malik, M.; Britten, J.L.; DeAngelis, A.; Sitler, C.; Moran, S.; Roura-Monllor, J.A.; Driggers, P.; Catherino, W.H. Curcumin inhibits human leiomyoma xenograft tumor growth and induces dissolution of the extracellular matrix. F&S Sci. 2023, 4, 74–89.
  55. Ciebiera, M.; Ali, M.; Prince, L.; Jackson-Bey, T.; Atabiekov, I.; Zgliczyński, S.; Al-Hendy, A. The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids. J. Clin. Med. 2020, 9, 1479.
  56. Touré, A.; Xueming, X. Flaxseed Lignans: Source, Biosynthesis, Metabolism, Antioxidant Activity, Bio-Active Components, and Health Benefits. Compr. Rev. Food Sci. Food Saf. 2010, 9, 261–269.
  57. Ganbold, M.; Shimamoto, Y.; Ferdousi, F.; Tominaga, K.; Isoda, H. Antifibrotic effect of methylated quercetin derivatives on TGFβ-induced hepatic stellate cells. Biochem. Biophys. Rep. 2019, 20, 100678.
  58. Ho, Y.; Yang, Y.-C.S.; Chin, Y.-T.; Chou, S.-Y.; Chen, Y.-R.; Shih, Y.-J.; Whang-Peng, J.; Changou, C.A.; Liu, H.-L.; Lin, S.-J.; et al. Resveratrol inhibits human leiomyoma cell proliferation via crosstalk between integrin αvβ3 and IGF-1R. Food Chem. Toxicol. 2018, 120, 346–355.
  59. Koushki, M.; Amiri-Dashatan, N.; Ahmadi, N.; Abbaszadeh, H.; Rezaei-Tavirani, M. Resveratrol: A miraculous natural compound for diseases treatment. Food Sci. Nutr. 2018, 6, 2473–2490.
  60. Wu, H.-L.; Chuang, T.-Y.; Al-Hendy, A.; Diamond, M.P.; Azziz, R.; Chen, Y.-H. Berberine inhibits the proliferation of human uterine leiomyoma cells. Fertil. Steril. 2015, 103, 1098–1106.
  61. Chuang, T.-Y.; Min, J.; Wu, H.-L.; McCrary, C.; Layman, L.C.; Diamond, M.P.; Azziz, R.; Al-Hendy, A.; Chen, Y.-H. Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1. Reprod. Sci. 2017, 24, 1005–1013.
  62. Wasternack, C. Jasmonates: An Update on Biosynthesis, Signal Transduction and Action in Plant Stress Response, Growth and Development. Ann. Bot. 2007, 100, 681–697.
  63. Anand David, A.V.; Arulmoli, R.; Parasuraman, S. Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid. Pharmacogn. Rev. 2016, 10, 84–89.
  64. Filomeno, M.; Bosetti, C.; Bidoli, E.; Levi, F.; Serraino, D.; Montella, M.; La Vecchia, C.; Tavani, A. Mediterranean diet and risk of endometrial cancer: A pooled analysis of three Italian case-control studies. Br. J. Cancer 2015, 112, 1816–1821.
  65. Ale, M.T.; Mikkelsen, J.D.; Meyer, A.S. Important determinants for fucoidan bioactivity: A critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds. Mar. Drugs 2011, 9, 2106–2130.
  66. Kim, J.K.; Park, S. U Current results on the biological and pharmacological activities of Indole-3-carbinol. Excli. J. 2018, 17, 181–185.
  67. Cho, S.; Kim, S.; Jin, Z.; Yang, H.; Han, D.; Baek, N.-I.; Jo, J.; Cho, C.-W.; Park, J.-H.; Shimizu, M.; et al. Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABAA receptors and shows hypnotic effects. Biochem. Biophys. Res. Commun. 2011, 413, 637–642.
  68. Lin, P.-H.; Kung, H.-L.; Chen, H.-Y.; Huang, K.-C.; Hsia, S.-M. Isoliquiritigenin Suppresses E2-Induced Uterine Leiomyoma Growth through the Modulation of Cell Death Program and the Repression of ECM Accumulation. Cancers 2019, 11, 1131.
  69. Lila, M.A.; Burton-Freeman, B.; Grace, M.; Kalt, W. Unraveling Anthocyanin Bioavailability for Human Health. Annu. Rev. Food Sci. Technol. 2016, 7, 375–393.
  70. Lee, A.W.; Eata, V. Association of environmental phenols with endometriosis and uterine leiomyoma: An analysis of NHANES, 2003–2006. Reprod. Toxicol. 2022, 113, 30–34.
  71. Chen, N.-N.; Han, M.; Yang, H.; Yang, G.-Y.; Wang, Y.-Y.; Wu, X.-K.; Liu, J.-P. Chinese herbal medicine Guizhi Fuling Formula for treatment of uterine fibroids: A systematic review of randomised clinical trials. BMC Complement Altern. Med. 2014, 14, 2.
  72. Castro, L.; Gao, X.; Moore, A.B.; Yu, L.; Di, X.; Kissling, G.E.; Dixon, D. A High Concentration of Genistein Induces Cell Death in Human Uterine Leiomyoma Cells by Autophagy. Expert. Opin. Environ. Biol. 2016, 5 (Suppl. S1).
  73. Tuzcu, M.; Sahin, N.; Ozercan, I.; Seren, S.; Sahin, K.; Kucuk, O. The effects of selenium supplementation on the spontaneously occurring fibroid tumors of oviduct, 8-hydroxy-2’-deoxyguanosine levels, and heat shock protein 70 response in Japanese quail. Nutr. Cancer 2010, 62, 495–500.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Primary Health Care
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Somayeh Vafaei
,
Michał Ciebiera
,
Mervat M. Omran
,
Mohammad Mousaei Ghasroldasht
,
Qiwei Yang
,
Tanya Leake
,
Rochelle Wolfe
,
Mohamed Ali
,
Ayman Al-Hendy
View Times: 406
Revisions: 2 times (View History)
Update Date: 19 Dec 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback